Zacks Investment Research Downgrades Fibrocell Science (FCSC) to Sell
Fibrocell Science (NASDAQ:FCSC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Several other research firms have also issued reports on FCSC. ValuEngine raised Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. HC Wainwright set a $22.00 target price on Fibrocell Science and gave the stock a “buy” rating in a research note on Thursday, August 9th.
Fibrocell Science (NASDAQ:FCSC) last posted its earnings results on Thursday, August 9th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.50). analysts forecast that Fibrocell Science will post -3.31 earnings per share for the current year.
A hedge fund recently raised its stake in Fibrocell Science stock. Renaissance Technologies LLC increased its position in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 37.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 162,281 shares of the company’s stock after acquiring an additional 44,584 shares during the period. Renaissance Technologies LLC owned about 1.74% of Fibrocell Science worth $439,000 at the end of the most recent quarter. 25.79% of the stock is owned by institutional investors.
About Fibrocell Science
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Read More: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.